Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 20,139 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,139 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00. Following the completion of the transaction, the chief executive officer directly owned 844,870 shares in the company, valued at approximately $1,689,740. The trade was a 2.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Performance

Shares of SERA opened at $2.00 on Thursday. The stock has a 50 day moving average price of $2.05 and a two-hundred day moving average price of $2.02. The firm has a market capitalization of $78.90 million, a P/E ratio of -2.99 and a beta of 0.98. Sera Prognostics, Inc. has a 52 week low of $1.56 and a 52 week high of $3.95.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. On average, equities analysts forecast that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Arkadios Wealth Advisors bought a new stake in Sera Prognostics in the 1st quarter valued at about $25,000. Lido Advisors LLC purchased a new stake in shares of Sera Prognostics during the 3rd quarter valued at approximately $68,000. Cetera Investment Advisers purchased a new stake in shares of Sera Prognostics during the 4th quarter valued at approximately $74,000. Qube Research & Technologies Ltd bought a new position in Sera Prognostics in the 2nd quarter worth approximately $92,000. Finally, Two Sigma Investments LP bought a new position in Sera Prognostics in the 3rd quarter worth approximately $97,000. Institutional investors own 54.64% of the company’s stock.

Wall Street Analysts Forecast Growth

SERA has been the subject of several analyst reports. Weiss Ratings downgraded shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Craig Hallum assumed coverage on Sera Prognostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.